What is the current Price Target for the Dyne Therapeutics Inc stock?

The average Dyne Therapeutics Inc target price is $47.86. This is 408.04% higher than the current stock price. The highest price target is 600.64%, the lowest is 80.47%. 14 Analysts have issued a price target Dyne Therapeutics Inc 2026 .

How high will the Dyne Therapeutics Inc stock rise?

No reliable answer can be given as to how high the Dyne Therapeutics Inc stock will rise. The performance of stocks, including the Dyne Therapeutics Inc stock, depends on a variety of factors, such as the general economic situation, the company's business results, investor expectations and global events.

What's going on with the Dyne Therapeutics Inc stock today?

The performance of Dyne Therapeutics Inc stock on any given day can be influenced by various factors, such as market conditions, industry trends, company news and global events.

Why did the Dyne Therapeutics Inc stock fall?

The decline in Dyne Therapeutics Inc stock may be due to a variety of factors, such as market conditions, industry trends, company news, macroeconomic events or changes in investor expectations. It is important to note that stock markets are inherently volatile and the performance of an individual stock on any given day is not necessarily indicative of its long-term performance.

What is a price target?

A price target is an estimate by an analyst or investment bank of where a company's stock price could be in a certain period of time, usually 12 months.

Dyne Therapeutics Inc Forecast, price target & analysts

$8.24

12.53% today

Nasdaq, Apr 04, 07:48 pm CET

ISIN

US26817R1086

Symbol

DYN

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Biotechnology

Overview Dividends Analysts Charts News Strategies

Dyne Therapeutics Inc Target price 2025 - Analyst rating & recommendation

Dyne Therapeutics Inc Classifications & Recommendation:

Buy

93%

Hold

Dyne Therapeutics Inc Price Target

Target Price	$47.86
Price	$9.42
Potential	408.04% register free of charge
Number of Estimates	14

	14 Analysts have issued a price target Dyne Therapeutics Inc 2026 . The average Dyne Therapeutics Inc target price is $47.86. This is 408.04% register free of charge higher than the current stock price. The highest price target is $66.00 600.64% register free of charge , the lowest is $17.00 80.47% register free of charge .
	A rating was issued by 14 analysts: 13 Analysts recommend Dyne Therapeutics Inc to buy, 1 to hold and 0 to sell.
	Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
	Analyst Estimates: Analysts believe that the Dyne Therapeutics Inc stock has an average upside potential 2026 of 408.04% register free of charge . Most analysts recommend the Dyne Therapeutics Inc stock at Purchase.

Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2029

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually

	Dec '24	2025 Estimates
Earnings Per Share $	-3.37	-3.65
	14.68%	8.31%
P/E		negative

6 Analysts have issued a Dyne Therapeutics Inc forecast for earnings per share. The average Dyne Therapeutics Inc EPS is

Unlock

. This is

Unlock

than earnings per share in the financial year 2024. The highest EPS forecast is

Unlock

, the lowest is

Unlock

This results in the following potential growth metrics and future valuations:

2024	$-3.37	14.68%
2025	$-3.65 8.31% Unlock
2026	$-3.62 0.82% Unlock
2027	$-2.69 25.69% Unlock
2028	$0.25 109.29% Unlock
2029	$2.61 944.00% Unlock

Current	-2.81	61.03%
2025	-2.58 8.19% Unlock
2026	-2.61 1.16% Unlock
2027	-3.50 34.10% Unlock
2028	37.68 1,176.57% Unlock
2029	3.61 90.42% Unlock

Dyne Therapeutics Inc...

Current Dyne Therapeutics Inc Upgrades & Downgrades

Create a Premium account to unlock Upgrades/Downgrades. Learn more

Analyst	Rating	Action	Date
JP Morgan	Locked ➜ Locked	Locked	Mar 21 2025
HC Wainwright & Co.	Locked ➜ Locked	Locked	Mar 17 2025
Chardan Capital	Locked ➜ Locked	Locked	Mar 17 2025
BMO Capital	Locked ➜ Locked	Locked	Mar 12 2025
Scotiabank	Locked ➜ Locked	Locked	Mar 07 2025
Chardan Capital	Locked ➜ Locked	Locked	Feb 28 2025
HC Wainwright & Co.	Locked ➜ Locked	Locked	Feb 28 2025

Analyst Rating	Date
Locked JP Morgan: Locked ➜ Locked	Mar 21 2025
Locked HC Wainwright & Co.: Locked ➜ Locked	Mar 17 2025
Locked Chardan Capital: Locked ➜ Locked	Mar 17 2025
Locked BMO Capital: Locked ➜ Locked	Mar 12 2025
Locked Scotiabank: Locked ➜ Locked	Mar 07 2025
Locked Chardan Capital: Locked ➜ Locked	Feb 28 2025
Locked HC Wainwright & Co.: Locked ➜ Locked	Feb 28 2025

Discover more stocks with a high price target

Novo Nordisk 83.92%

Coinbase Global, Inc. 83.53%

BioNTech SE - ADR 50.09%

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now